H ealth care in the United States is increasingly being delivered during ambulatory care visits. 1 As new investment in health care shifts from the inpatient to outpatient setting, the role of ambulatory clinical pharmacists (CP) are expanding. While dispensing pharmacists provide clinical screening and patient education for potential drugrelated problems, CPs provide services that complement the care provided by dispensing pharmacists by directly advising and educating other health care providers and patients on appropriate pharmaceutical use and dosing.
H ealth care in the United States is increasingly being delivered during ambulatory care visits. 1 As new investment in health care shifts from the inpatient to outpatient setting, the role of ambulatory clinical pharmacists (CP) are expanding. While dispensing pharmacists provide clinical screening and patient education for potential drugrelated problems, CPs provide services that complement the care provided by dispensing pharmacists by directly advising and educating other health care providers and patients on appropriate pharmaceutical use and dosing.
Initial involvement of CPs in the ambulatory setting occurred primarily in the primary care setting. Early studies examined the impact of CPs and reported improved outcomes with clinical pharmacy management of care on patient compliance, [2] [3] [4] [5] [6] diabetes, 7 patient-specific drug information, 8 and treatment of infections. 9 Systematic reviews of CP involvement in ambulatory settings note that while the quality of research (e.g., weak methodology, small sample sizes) is limited, the participation of CPs in health care has resulted in positive cost-effective care. [10] [11] [12] A 2010 Cochrane review summarizing randomized controlled studies of CP involvement noted that most of the studies meeting inclusion took place in a primary care or community pharmacy setting rather than a specialties setting. 12 CP involvement in ambulatory specialty areas has expanded into a broader array of disease states. Reports noting CP involvement in psychiatry practices were first published in the 1970s. 13, 14 Currently, settings with CP involvement in specialty clinics include primarily health maintenance organizations, teaching institutions, and Veterans Affairs (VA) health systems. 15 Other nonfee-for-service settings that may have specialty CP involvement include community clinics and other non-VA government health care systems. Systematic reviews summarizing the roles and/or impact of CP involvement in various specialty areas have been published. These areas include mental health, [16] [17] diabetes, [18] [19] nephrology, [20] [21] heart failure, 22 asthma, 23 Alzheimer's disease, 24 and antibiotic management. 25 Knapp et al.'s (2005) 2004 survey of 233 ambulatory sites with CP involvement reported that the most common area of specialty CP involvement was oncology (28% of participating sites). 15 Less than 10% of participating sites had CP involvement in neurology, heart failure, or psychiatry management, while involvement in other medical specialties was not reported by most participating sites. 15 Accordingly,
C O M M E N TA R Y
CP involvement in many specialties in the ambulatory setting has not been described in the literature, and little research on the clinical and economic outcomes of CP involvement has been conducted in specialty settings. [16] [17] [18] The Kaiser Permanente Colorado (KPCO) Pharmacy Department represents a close partnership of ambulatory dispensing pharmacies (i.e., pharmacy operations) with clinical pharmacy services located in patient care areas. 26, 27 The KPCO Clinical Pharmacy Specialty Services (CPSS) CPs are integrated with medical office practices and work collaboratively with physicians to provide direct patient care, focused drug therapy expertise, and disease state management. This commentary provides a description of the KPCO's CPSS and its individual clinical pharmacy specialty services but does not attempt to undertake additional outcomes analysis for each service, as a case study supporting the expansion of CP involvement into medical specialty care. demonstrate competence and skill in their respective clinical area of practice. Basic characteristics of individual CPSS practice areas are described in Table 1. A common characteristic shared across all CPSS practice areas is partnership with the physician leadership of each medical specialty. Partnership facilitates the sponsorship needed for successful implementation of specialty departmentspecific initiatives. Partnering with physician leadership also provides a point of contact for sharing evidence. Furthermore, partnership is required to develop collaborative drug therapy management (CDTM) guidelines, since the Colorado Board of Pharmacy permits CDTM guidelines that allow CPs to start, stop, and/or adjust medications for patients with specified diseases. Physician leadership's ongoing support of the CPSS's initiatives is facilitated by the documentation of the CPSS's positive effects on patient outcomes.
Typically, physicians and other health care providers involve CPSS CPs in patient care activities by sending referrals via a virtual "in-basket" within the KPCO electronic medical record (EMR; HealthConnect, Epic Systems Corporation, Madison, Wisconsin). If appropriate, the CP contacts the patient by phone to discuss the medication issue. After completing necessary patient care activities, progress notes are sent back to physicians for review via the EMR. The CPs can remotely access colleagues' in-baskets in cases where cross-coverage is needed and communicate directly with CPs in other areas (e.g., primary care). The EMR facilitates clinical pharmacy practice and allows communication to enhance care efficiency, enables interventions on concomitant disease states, maximizes the number of patients the CPs can impact, and empowers multidisciplinary teamwork across medical offices.
A typical day for a CPSS CP can vary depending on the specific specialty service. Nevertheless, there are similarities across services. For example, the majority of every CP's day is spent addressing patient-specific medication questions in the clinic, during rounds, or, most often, via the EMR. In addition, direct patient care encounters can be performed. Nondirect patient care activities, such as precepting students or residents; developing clinical guidelines; and prescribing guidelines, monographs, or patient and provider education materials, are addressed as needed. Because the CPSS CP serves as a resource to the health plan for a given specialty, effort can be spent in multidisciplinary committee, specialty department, or pharmacy department meetings to provide specialty care input. Additionally, many CPs can devote their time serving on inter-Kaiser Permanente health plan committees to develop specialty care guidance.
The vast majority of direct patient contact is performed telephonically. None of the CPs have regular in-person appointments with patients, although some CPs may see a patient as part of a scheduled visit with an interdisciplinary team. Because most of the CPs are located physically in patient care designed for the CP to collaborate closely with physicians to address complex medication-related issues and provide detailed medication information and patient-specific recommendations. Since 1990, additional CP specialty services have been added. The rationale for the additional services was an aspiration to better manage appropriate prescribing of high-cost medications (e.g., gastroenterology, neurology, oncology) and support for vulnerable populations at risk of polypharmacy and hospital admission (e.g., palliative care, continuing care).
At present, CPSS has expanded to support 16 specialty areas with additional core responsibilities, including (a) delivering continuing education programs and staff development in-services; (b) developing guidelines for disease state management; (c) contributing to pharmacy student and resident experiential education; (d) supporting patient safety, quality, and affordability initiatives to promote appropriate and cost-effective drug therapy management; (e) conducting pharmacy practicerelated research; and (f) documenting the value of clinical interventions. These responsibilities are achieved through both population management programs and the focus on the medication-related problems of individual patients.
Population management at KPCO involves providing pharmaceutical care for an entire population, not just individuals who seek care. Through targeted patient identification and risk stratification strategies and the development of disease treatment guidelines and protocols, CPs are able to impact care for sizeable numbers of patients. For example, CP population management strategies include interventions with multiple patients who were identified as having been receiving highcost drugs and those who recently initiated nonpreferred therapies to interchange them to lower-cost, appropriate therapies. Additionally, CPs have created and maintained patient disease registries that allow them to identify and intervene with patients who would benefit from medication management. As the National Committee for Quality Assurance (NCQA) uses Health Effectiveness Data and Information Set (HEDIS) measures to compare the quality of care provided by health plans and their contracted providers, 28,29 the CPSS contributes to KPCO's HEDIS measures through individual treatment recommendations, specific initiatives, and guideline development. For example, the Behavioral Health and Neurology CPs have led an initiative to improve anticonvulsant medication monitoring by outreaching to members via an intervention letter.
■■ Service Structure
All CPSS CPs have a doctor of pharmacy degree and postgraduate year 2 residency training or equivalent professional experience (e.g., meaningful postgraduate ambulatory clinical practice). Additionally, they are required to earn and maintain board certification in an appropriate pharmaceutical specialty (e.g., Pharmacotherapy Specialist, Ambulatory Care Pharmacist, Oncology Pharmacist, Psychiatric Pharmacist) to and/or provider office areas, in-person referrals can be made, also. Additionally, some care is initiated based on a quality or safety initiative (e.g., interchange to a preferred agent, medication recalls).
All CPs provide training for both pharmacy residents and students. Residency training is offered as part of an American Society of Health-System Pharmacy-accredited ambulatory pharmacy residency; however, all specialty services rotations are considered elective. No specific clinical activities are dependent on resident or student involvement. In a typical year, each specialty serves as a preceptor for 1 to 3 residents and 2 to 3 students. CPs are involved in didactic or other pharmacy teaching at 2 local pharmacy schools.
■■ Service Descriptions
The following are descriptions of individual CPSS CP practice areas that highlight unique practice aspects, health care outcomes, and contributions to pharmacy practice.
Asthma/Allergy
The Asthma/Allergy CP supports physicians, nurses, and pharmacy staff with clinical decision making regarding allergy and asthma pharmacotherapy. This CP develops and updates KPCO guidelines for the treatment of asthma with the goal of improving appropriate medication therapy for asthma as defined by the NCQA HEDIS measures. 30 Direct patient care is provided utilizing CDTM guidelines for asthma, allergic rhinitis, gastroesophageal reflux disease, and chronic hives. Most care under CDTM is done as part of a physician-approved initiative with direct physician referral. This CP supports nurses and pharmacy staff in reducing the overuse of short-acting beta-agonists and increasing the use of controller medications in patients with asthma. 30 Another important initiative aims to reduce the proportion of patients using long-acting beta agonist monotherapy and increasing the appropriate use of inhaled corticosteroids. Additional activities include participation in KPCO guideline development for acute and chronic sinusitis and standardizing the management of anaphylaxis cases.
Behavioral Health
Three Behavioral Health CPs ensure the safe and appropriate use of psychotropic medications through direct patient care activities and population management strategies at 3 outpatient clinics and 1 contracted acute psychiatric hospital. These CPs collaborate with a diverse group of practice areas including psychiatry, chemical dependence, primary care, obstetrics and gynecology, and pharmacy. Upon referral, they address specific behavioral health medication-related problems or provider questions, primarily following review of patients' EMR and pharmacy records. They also emphasize to providers 
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evidence-based prescribing for common problems such as depression 31, 32 and schizophrenia. [33] [34] [35] Behavioral Health CPs are frequently asked to assist with management of treatmentresistant disease states, medication use during pregnancy and lactation, drug interactions, drug-related adverse events, and medication use in special populations (e.g., pediatrics, geriatrics, developmental disorders such as autism).
Drug initiatives that promote the cost-effective use of brand name (e.g., aripiprazole) versus generic (e.g., risperidone) second-generation antipsychotics (SGA) with a goal of cost avoidance for the organization are important focus areas for Behavioral Health CPs. Patient safety is another important area of focus for Behavioral Health CPs. For example, a project to ensure safe use of citalopram in response to safety warnings regarding the potential for electrocardiogram changes including prolonged QT interval 36 was led by the Behavioral Health CPs. A Behavioral Health CP outcomes research project found that patients newly initiated on SGA therapy were not monitored properly for changes in blood pressure, weight, fasting blood glucose, or lipid profiles. 37 Behavioral Health CPs subsequently developed a workflow for KPCO providers to ensure that such metabolic monitoring occurs appropriately for patients initiated on SGA therapy.
Cardiology
Two Cardiology CPs provide support to cardiologists, cardiology nurses, and their patients who have various cardiac conditions. Their primary roles include the development of best practice guidelines for the use of antiplatelet therapy in patients receiving drug-eluting stents or with acute coronary syndromes and anticoagulant therapy for patients with atrial fibrillation. Cardiology CPs have established an amiodaronemonitoring service that has been shown to increase the frequency of recommended electrocardiogram and liver function monitoring compared with usual care. 38 A CDTM guideline allows Cardiology CPs to manage thyroid and liver abnormalities for patients enrolled in the amiodarone-monitoring service. In addition, using a registry of patients with pulmonary hypertension, Cardiology CPs facilitate liver function and pregnancy testing as required by Risk Evaluation and Mitigation Strategies. 39 Furthermore, they assist in the development of KPCO medication-use guidelines for heart failure and treatment of clinically significant anemia in patients with heart failure.
Continuing Care
Three Continuing Care CPs support assisted living and longterm care facility health care providers by providing pharmacotherapy recommendations for KPCO patients residing in these facilities. In addition, they round with interdisciplinary health care teams at posthospital facilities to ensure the continuity of patient care. During consultation, Continuing Care CPs screen institutionalized patients' medications for appropriate dosing, indication, interactions, therapeutic duplication, and missing therapies. Additionally, they serve as a drug information resource for rounding physicians and other providers.
Continuing Care CPs assisted in the development of a computerized pharmacy alert system that reduces the risk of prescribing potentially inappropriate medications to the elderly. 40 These CPs support other initiatives to reduce the use of highrisk medications by the elderly and improve the management of osteoporosis in women who have suffered a fracture. One initiative successfully interchanged patients aged ≥ 65 years who were receiving diazepam, a long-acting benzodiazepine that should be avoided in elderly patients, to safer alternative treatments.
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Dementia Care
An interdisciplinary team, including 1 Dementia Care CP, provides services to patients with dementia and their families. Pharmacy services provided by the Dementia Care CP include screening for possible medication-related causes of memory problems, optimizing medication management, providing recommendations for dementia-related behaviors and psychiatric disorders, and educating providers on dementia-related medication concerns. This CP's recommendations/education are provided during weekly interdisciplinary team rounds. Patients who cannot be seen in clinic receive specialty consults from this CP through telephone and e-mail encounters.
Diabetes/Endocrinology
The Diabetes/Endocrinology CP provides population management and consultative services for endocrinologists, primary care physicians, and multidisciplinary diabetes care management teams who care for patients with diabetes and other endocrine conditions. Support for the development of KPCO clinical guidelines, communication of endocrinology-related clinical issues and updates, and representation on a diabetes care policy-setting committee are additional responsibilities. Specific projects include the implementation of system measures for the safe use of concentrated U-500 insulin, promotion of cost-effective use of diabetes therapy, and development of KPCO guidelines and treatment algorithms for specialty therapies (e.g., growth hormones). Additionally, the Diabetes/ Endocrinology CP communicates safety alerts to providers (e.g., the U.S. Food and Drug Administration's pioglitazone warning). 42, 43 The Diabetes/Endocrine CP developed and coordinated a novel intervention that increased the use of evidence-based cardiovascular risk reduction therapies in patients with diabetes. This program sent letters to patients with diabetes who were not receiving lovastatin. The letter explained to patients the benefits of lovastatin therapy and gave them instructions on how to purchase a prewritten lovastatin prescription and receive baseline and follow-up monitoring laboratory tests. 44 This project reinforced best practice prescribing and intervention through identification of candidates for lisinopril and aspirin therapy. Other outcomes research conducted by the Diabetes/Endocrine CP demonstrated that adjunct pioglitazone therapy in real-world patients with type 2 diabetes was associated with clinically meaningful reductions in hemoglobin A1c levels. 45 
Gastroenterology
The Gastroenterology (GI) CP serves as a GI pharmacotherapy expert and provides patient consultative services, medicationrelated literature reviews, and gastroenterology-related education to GI physicians and other health care providers. The GI CP developed a KPCO guideline regarding the use of novel hepatitis C agents to ensure appropriate clinical use due to their expensive side-effect profile and potential for serious interactions. 46 Using this guideline, the GI CP collaborates with GI physicians to ensure that only appropriate candidates receive these therapies. Patient education tools are provided by this CP with a goal of increasing adherence to GI pharmacotherapies. The GI CP increased the cost-effective use of rifaximin in patients with end-stage liver disease and experiencing hepatic encephalopathy by promoting the appropriate use of twice daily instead of three times daily dosing of rifaximin. 47 In addition, the GI CP assists in monitoring patients with microscopic colitis to reduce the number of patients initiated and maintained on systemic corticosteroids.
48,49
Infectious Disease
The Infectious Disease (ID) CP supports ID and primary care physicians by providing ID-related medication review, assessment, information, and education. The ID CP plays a crucial role in the development of KPCO guidelines for the selection of antibiotic, antifungal, and antiviral medications. Another important role for this CP is to address immunization questions related to appropriateness, dosing, and adverse effects. In addition, this CP assists in guideline development for annual influenza vaccinations, new vaccines, and new recommendations for existing vaccines.
The ID CP provides recommendations, via the EMR, for patients with human immunodeficiency virus infection, including identification of serious medication-related problems, confirming vaccination against hepatitis A and invasive pneumococcal disease in appropriate patients, cardiac risk assessment, and ensuring attainment of hyperlipidemia treatment targets. Furthermore, the ID CP provides consultation for KPCO's Clinical Pharmacy International Travel Clinic, a novel service that provides pretravel advice to KPCO members to decrease their risk of travel-related diseases.
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Inpatient
The Inpatient CP provides direct and indirect patient care services at 3 KPCO contract hospitals. While technically not an ambulatory service, the Inpatient CP focuses on transitions of care to the ambulatory setting. Thus, this CP is considered a part of the ambulatory care team. Services range from providing pharmacotherapy consults to serving on committees that develop standardized order sets and evidence-based treatment guidelines. A major focus for the Inpatient CP is ensuring smooth transitions of care, with projects targeting improvements in medication reconciliation and identification and management of medication-related problems. The Inpatient CP implemented a nonformulary medication review process for discharge medications that is designed to control medication costs. The Inpatient CP also developed programs promoting the use of appropriate inpatient pharmacologic venous thromboembolism (VTE) and stress ulcer prophylaxis. The need for these efforts was highlighted by research conducted by the Inpatient CP that confirmed a strong association between outpatient VTE diagnosis and previous hospitalization and identified that VTE prophylaxis continues to be underutilized in hospitalized patients.
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Nephrology
The Nephrology CP provides population management and consultative services for patients with chronic kidney disease and those receiving renal replacement therapy. Nephrology CP quality initiatives include collaborating with primary care providers to identify care gaps, such as undiagnosed hypertension, hyperlipidemia, and bone mineral disease, to improve the management of patients with chronic kidney disease. This CP provides support to not only internal KPCO providers but also contracted nephrology and dialysis providers. The Nephrology CP provides direct patient care through participation in a multidisciplinary kidney care program that has been shown to slow the rate of renal function decline when compared with usual care. 52 Additionally, this CP supports nephrology-related education and development of KPCO guidelines for managing chronic kidney disease.
The Nephrology CP assisted with the development and implementation of the Drug Renal Alert Pharmacy Program (DARP) that alerts pharmacists at the time of prescription dispensing about possible medication selection and dosing errors for patients with renal insufficiency. In a randomized trial, the DARP program led to a lower rate of medication errors compared with usual care. 53 The Nephrology CP also investigated the impact of an annual cap on brand-name prescription medication expenditures on sevelamer adherence and discontinuation for patients with end-stage renal disease. Patients with a capped brand-name prescription medication benefit were associated with fewer days of medication use compared with patients without a capped benefit. include education related to end-of-life medication use and recommendations for symptom control for patients with a life-limiting illness (e.g., cancer, chronic obstructive pulmonary disease, heart failure). Palliative Care CPs make recommendations related to pain control, dyspnea, fatigue, nausea, and depression. A more detailed description of the KPCO home-based palliative care position has been published previously. 58 Scholarly activities for the Palliative Care CPs include an investigation of anticoagulation use at the end of life that revealed palliative care patients had more frequent nternational Normalized Ratio (INR) measurements and were more likely to have INR measurements outside of the target range than matched controls.
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Primary Care House Call
The Primary Care House Call CP provides support to physicians and nurses providing medical care to homebound patients who are physically unable to be seen in a medical office. This CP's primary roles include identifying the use of medications not recommended for the elderly and the reduction of polypharmacy. The Primary Care House Call CP provides recommendations for a wide variety of medical conditions including dementia, osteoporosis, chronic obstructive pulmonary disease, depression, and uncontrolled pain. Provider support by this CP is delivered primarily by telephone and via the EMR.
Senior Emergency Department
A Senior Emergency Department (ED) CP is embedded in 1 of KPCO's contracted EDs. This CP collaborates with an interdisciplinary team to provide pharmaceutical care for patients aged ≥ 65 years presenting to the ED. The goal of this service is to optimize medication therapy, particularly for frail seniors who have multiple comorbidities. The roles of the Senior ED CP include reviewing medications to identify potential medication-related causes for the patient's ED visit, providing comprehensive medication recommendations to both ED and inpatient (in case of admission) providers, medication reconciliation, medication therapy optimization for seniors, and identifying inappropriate medication use in seniors (a HEDIS measure). Another important role is providing direct patient care when answering medication-related questions from senior patients and/or their caregivers.
Weight Management
The Weight Management CP assists primary care physicians and other providers with pharmacotherapy recommendations for patients seeking to lose weight. This CP's primary role involves screening to ensure patients meet criteria for weightloss medication use based on body mass index and risk for side effects. An additional role is assisting providers in adjustments in therapy for hypertension, diabetes, and hyperlipidemia for
Neurology
The Neurology CP provides a combination of consultative and population management services to support the neurology and primary care providers. Support is provided through education and development of clinical guidelines for various neurologic diseases. The Neurology CP assisted in the development of a lab-monitoring program for high-risk immunosuppressive and immune modulatory medications. In addition, this CP assisted in the development of KPCO adult and pediatric migraine guidelines for primary care providers, including EMR-based tools for the acute and chronic management of migraine and tension-type headaches.
When acetaminophen/isometheptene/dichloralphenazone was removed from the market, the Neurology CP coordinated efforts to provide alternative migraine medications for affected patients. Furthermore, this CP developed patient instruction sheets for the safe use of complementary/alternative medicines in neurology. The Neurology CP participates in scholarly activities, including research on the effects of therapeutic interchange of brand to generic phenytoin among patients with epilepsy. This investigation identified no increased risk of seizure when branded phenytoin was interchanged to a generic equivalent.
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Oncology
The primary roles for the 2 Oncology CPs include reviewing and recommending chemotherapy regimens, preventing and/ or managing chemotherapy-induced toxicity, and providing supportive care to oncology patients. Areas of supportive care include, but are not limited to, nausea and vomiting prevention and treatment, pain management, infection prevention and treatment, and therapeutic medication monitoring. The Oncology CPs have been instrumental in developing KPCO guidelines for monitoring oral chemotherapy. Additional projects include provider education regarding critical drug-drug interactions between tamoxifen and CYP2D6 inhibitors, as well as facilitating the transition from brand to generic aromatase inhibitors for appropriate patients.
The Oncology CPs developed education materials that encourage the use of pamidronate over zoledronic acid for the treatment of bone lesions due to multiple myeloma and breast cancer. Scholarly activities include participating in National Cancer Institute-sponsored investigations that validated the use of administrative clinical data to capture breast cancer chemotherapy exposure 56 and identified predictors of first-line chemotherapy use among adults with advanced non-small cell lung cancer.
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Palliative Care Three Palliative Care CPs assist interdisciplinary teams to deliver appropriate palliative care in the inpatient, medical office, and home-based settings. Their primary responsibilities have an understanding of the potential impact of the specialty services and training in the design, conduction, analysis, and reporting of experimental research techniques. Furthermore, it would require upfront planning to engage in research prior to the implementation of a specialty service. Health care administrators and third-party payers require an understanding of the savings and benefits that can be attained through CP involvement in medical specialties. Such evidence can support the use of CPs to address high-cost, specialty medications through the development of cost-effective guidelines, monitoring programs, and tailored interventions to impact quality, safety, and cost.
With health care reform now in the forefront of health system and physician leadership, some similarities exist between the KPCO integrated health delivery system and Accountable Care Organizations (ACOs). ACOs are groups of hospitals and physicians that accept joint responsibility for the cost and quality of care provided to Medicare beneficiaries enrolled in Medicare Parts A and B.
63 This can be accomplished through coordinated care and chronic disease management. 63 The premise of the accountable care model is to hold ACOs responsible for the quality and efficiency of care provided through financial incentives tied to total cost of care and quality measures. The financial incentives, if significant enough, could subsidize or otherwise completely support clinical pharmacy resources needed to meet quality metrics.
As private physician groups are likely to partner with other third-party payers to provide safe, high-quality, and costeffective care to patients, a focus on developing health systems that integrate clinical pharmacy specialty services to help achieve quality metrics may become more applicable to other organizations. We acknowledge that ACO-associated financial incentives alone may not be enough to support CP involvement in specialty areas. Thus, it is important to achieve payment reform that recognizes pharmacists as health care providers so that appropriate reimbursement for pharmaceutical services can occur. Until this happens, it may continue to be a challenge financially for private physician groups to support CP involvement in specialty areas.
As the CPSS continues to grow and expand at KPCO, it will become increasingly important to document interventions (e.g., amount of time focused on drug cost-minimization activities vs. patient outcomes-oriented activities) and value. So far, CPSS value has been proven to KPCO leadership through internally reported medication cost offsets and CPSS contributions to HEDIS measures and scholarly activities. Unfortunately, the CPSS CPs have been systematically documenting their internal value only since 2010. Having had a more robust system for documenting interventions and value at the outset of the CPSS would have provided more detailed information for analysis. A new system is being developed to better track monetary return on investment to assist in establishing justification for current CP positions and adding additional CP resources as patients prescribed very low calorie diets. Furthermore, the Weight Management CP assists with medication adjustments for patients before and after bariatric surgery and preparation of protocols for pre-and postsurgery medication management and presurgery diets.
■■ Discussion
The expanding scope of pharmacy practice is providing opportunities for CPs to develop expertise in areas that are established, as well as emerging, service lines within the pharmacy scope of work. Regardless of specialty practice, core responsibilities for pharmacists working in a clinical, ambulatory care setting remain essentially the same. Their key functions are to provide safe, high-quality, and cost-effective pharmaceutical care to patients. We have described a clinical pharmacy specialty service that employs these key functions to deliver care in 16 specialty areas. We outlined the structure of the CPSS and its practice areas, core responsibilities, and health care outcome goals.
While information on individual specialty clinical pharmacy practices have been described, [16] [17] [18] there is limited information published on a comprehensive clinical pharmacy specialty service encompassing multiple practices. While not designed specifically as a comprehensive clinical pharmacy specialty service, the U.S. Public Health Service (PHS) utilizes pharmacists in a variety of care settings that encompass some specialty services. 60 For example, CPs in the PHS staff chronic care specialty clinics in the Indian Health Service (IHS). These specialty clinics include anticoagulation, asthma, congestive heart failure, diabetes, dyslipidemia, immunization, and smoking cessation. 60 At KPCO, similar specialty areas are covered by the CPSS (asthma, congestive heart failure, diabetes, and immunization) and other clinical pharmacy services (e.g., the Clinical Pharmacy Anticoagulation and Anemia Drug Service). The specific roles and responsibilities within the IHS clinics are not available to compare and contrast with the KPCO CPSS.
As pharmaceutical costs continue to increase, economic evaluations of clinical pharmacy in the ambulatory care setting will become increasingly important. In a recent white paper commissioned by the American College of Clinical Pharmacists, Harris et al. (2008) highlighted the importance of documenting the economic value of clinical pharmacy interventions. 61 In medical specialties, use and cost of high cost medications continue to rise at an alarming rate. 62 CPs can directly impact the quality of patient care and medication expenses in the specialty setting given the complex and chronic nature of many of the disease states being treated. 16, 17 Pharmacy practice research that utilizes experimental or quasi-experimental study designs is needed to provide additional evidence of CPs' impact on specialty care and its associated costs. Accomplishing this would require substantial funding. In addition, it would require pharmacist researchers who appropriate. Data from this tracking will be analyzed and reported so as to share best pharmacy practices across health plans and systems.
■■ Conclusions
The KPCO CPSS has grown and evolved since its inception with an Infectious Disease CP over 20 years ago to involve 16 specialty service areas as of 2013. CPs in these specialty practice areas work in alignment with their respective multidisciplinary health care teams to strive to provide highquality, cost-effective care. In addition, the CPSS CPs have undertaken scholarly activities to document the value of CP involvement in specialty care. At KPCO, the CPSS has become integral to specialty medical practices such that its effect on individual patient care and population management strategies is recognized as essential to the provision of pharmaceutical care. Future well-designed research is essential to document and report CPs' interventions and the subsequent value they provide to health care. In addition, future efforts should be undertaken to provide detailed instructions on the development, implementation, and persistence of CP specialty services to provide other health systems with the information that they may need to establish their own CP specialty services.
